Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aptose Biosciences ( (TSE:APS) ) has provided an update.
Aptose Biosciences, a clinical-stage oncology biotech focused on precision small-molecule therapies for hematologic malignancies, is advancing its lead oral kinase inhibitor TUS for use as both monotherapy and in combination regimens in acute myeloid leukemia. The company targets unmet medical needs by designing agents that can enhance existing anti-cancer treatments without adding overlapping toxicities.
On March 23, 2026, Aptose announced that proxy advisory firm Glass Lewis recommended shareholders vote for its proposed plan of arrangement under which Hanmi Pharmaceutical and an affiliate would acquire all Aptose shares they do not already own. Glass Lewis also endorsed Aptose’s proposed corporate continuance from the CBCA to the ABCA, ahead of a reconvened special meeting set for March 31, 2026, where the board and special committee are unanimously urging shareholders to approve the deal and related resolutions, with closing still contingent on court and TSX approvals.
The most recent analyst rating on (TSE:APS) stock is a Hold with a C$2.50 price target. To see the full list of analyst forecasts on Aptose Biosciences stock, see the TSE:APS Stock Forecast page.
Spark’s Take on APS Stock
According to Spark, TipRanks’ AI Analyst, APS is a Neutral.
The score is held back primarily by very weak financial performance (no revenue, ongoing cash burn, negative equity and rising debt). Positive corporate catalysts (promising trial results and a pending acquisition) provide meaningful offset, while technical indicators are mixed-to-weak and valuation metrics are not supportive due to negative earnings and no dividend.
To see Spark’s full report on APS stock, click here.
More about Aptose Biosciences
Aptose Biosciences Inc. is a clinical-stage biotechnology company developing precision oncology medicines, with an initial focus on hematologic cancers. Its small-molecule pipeline aims to deliver single-agent efficacy and boost other anti-cancer regimens without overlapping toxicities, led by TUS, an oral kinase inhibitor in development for acute myeloid leukemia, including frontline triplet therapy in newly diagnosed AML patients.
YTD Price Performance: 5.19%
Average Trading Volume: 3,993
Technical Sentiment Signal: Sell
Current Market Cap: C$5.69M
For an in-depth examination of APS stock, go to TipRanks’ Overview page.